Abstract:ABSTRACT Ezetimibe inhibits Niemann-Pick C1-like 1 (NPC1L1) protein, which mediates intracellular cholesterol trafficking from the brush border membrane to the endoplasmic reticulum, where chylomicron assembly takes place in enterocytes or in the intestinal absorptive epithelial cells. Cholesterol is a minor lipid component of chylomicrons; however, whether or not a shortage of cholesterol attenuates chylomicron assembly is unknown. The aim of this study was to examine the effect of NPC1L1 inhibition on trans-epithelial lipid transport, and chylomicron assembly and secretion in enterocytes. Caco-2 cells, an absorptive epithelial model, grown onto culture inserts were given lipid micelles from the apical side, and chylomicron-like triacylglycerol-rich lipoprotein secreted basolaterally were analyzed after a 24-h incubation period in the presence of ezetimibe up to 50 μM. The secretion of lipoprotein and apolipoprotein B48 were reduced by adding ezetimibe (30%, p <0.01 and 34%, p <0.05, respectively). Additionally, ezetimibe accelerated intracellular apoB protein degradation by approximately 2.8-fold and activated sterol regulatory element binding protein 2 by approximately 1.5-fold: These are indicators whether the cells are sensing cellular cholesterol shortage. Thus, ezetimibe appeared to limit cellular cholesterol mobilization required for lipoprotein assembly. In such conditions, large lipid droplet formation in Caco-2 cells and the enterocytes in mice were induced, implying that unprocessed triglyceride was sheltered in these compartments. Although ezetimibe did not reduce the post-prandial lipid surge appreciably in triolein-infused mice, the results of the present study indicated that NPC1L1-mediated supply chylomicron with cholesterol may participate in a novel regulatory mechanism for the efficient chylomicron assembly and secretion.

Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Niemann–Pick C1-Like 1 and Cholesterol Uptake

The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1

The Development of the Key PNPC1L1 in Cholesterol Transport

Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine

Recent advances in the screening methods of NPC1L1 inhibitors

NPC1L1 inhibition disturbs lipid trafficking and induces large lipid droplet formation in intestinal absorptive epithelial cells

Inhibitory Effect of Isoliquiritigenin in Niemann-Pick C1-Like 1-Mediated Cholesterol Uptake

Progress in the Mechanism of Dietary Cholesterol Absorption

Ezetimibe Restores Biliary Cholesterol Excretion in Mice Expressing Niemann-Pick C1-Like 1 Only in Liver.

Ezetimibe: Its Novel Effects on the Prevention and the Treatment of Cholesterol Gallstones and Nonalcoholic Fatty Liver Disease

First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor

New azetidinone cholesterol absorption inhibitors

Fluorescent visualization and evaluation of NPC1L1-mediated vesicular endocytosis during intestinal cholesterol absorption in mice

Ezetimibe Inhibits Hepatic Niemann-Pick C1-Like 1 to Facilitate Macrophage Reverse Cholesterol Transport in Mice

Bile Acids-Mediated Intracellular Cholesterol Transport Promotes Intestinal Cholesterol Absorption and NPC1L1 Recycling

NPC1L1 Plays a Novel Role in Nonalcoholic Fatty Liver Disease

Virtual Screening for Cholesterol Absorption Inhibitors.

Inter-domain dynamics drive cholesterol transport by NPC1 and NPC1L1 proteins

Hepatic NPC1L1 Promotes Hyperlipidemia in LDL Receptor Deficient Mice